Research is converging on two key drivers of long COVID: persistent inflammation and tiny fibrin-based blood clots. While these findings explain the condition's widespread damage across organs, no proven treatments exist yet, leaving roughly 65 million people searching for answers.
Six years ago, a new coronavirus began spreading, and most people expected a quick recovery. Today, an estimated 65 million people worldwide are still living with symptoms that refuse to go away. Long COVID is defined as symptoms lasting at least two months after the initial SARS-CoV-2 infection, with no other clear medical explanation. For years, doctors struggled to explain why. Now, a clearer picture is finally emerging.
What long COVID actually does to your body
Scientists have known for a while that long COVID is not just 'in your head.' The symptoms span multiple organs, from brain fog to crushing fatigue, and the condition can damage the brain, heart, blood vessels, and immune system long after infection. But the underlying mechanisms have been harder to pin down.
A review published in January 2026 points to several overlapping biological problems, with two standing out: runaway inflammation and microscopic blood clots. These are not your typical clots. They are tiny, fibrin-driven structures that can block blood flow at the capillary level, starving tissues of oxygen throughout the body.
The inflammation and microclot connection
Long COVID patients show elevated levels of specific inflammatory markers called IL-1β, IL-6, and TNF-α. These are chemicals your immune system releases to fight threats. In long COVID, they stay switched on long after the virus is gone.
A January 2026 Research Briefing in Nature Immunology confirms that people with long COVID have sustained upregulation of chronic inflammatory pathways compared with people who fully recovered from the infection. The inflammation does not just simmer quietly. It actively damages tissue over time and points to potential new therapeutic targets.
How the spike protein creates hidden clots
This is where the research gets particularly interesting. A Nature study published in August 2024 revealed that fibrin, a protein normally involved in healthy blood clotting, interacts with the SARS-CoV-2 spike protein to create abnormal, proinflammatory blood clots. The researchers describe this process as systemic thromboinflammation.
These clots are not the large ones that cause strokes or heart attacks. They are microscopic, but their effects are serious. Fibrinogen is abundantly deposited in the lungs and brains of COVID-19 patients, and fibrinogen levels correlate with COVID-19 disease severity. Fibrin also drives damage through its inflammatory domain, triggering oxidative stress and macrophage activation in the lungs. So you get a vicious cycle: inflammation creates abnormal clots, and those clots trigger more inflammation.
Why there are still no treatments
Here is the frustrating part. Despite this growing understanding, there are no approved, evidence-based treatments for long COVID as of January 2026.
Antiviral drugs taken during the initial COVID-19 infection may reduce the risk of developing long COVID, but the exact size of that benefit remains unclear. Other contributing factors, like auto-immunity, gut bacteria disruptions, and impaired mitochondrial function, add further complexity to finding a single treatment.
Clear answers remain limited by small studies and a lack of large, definitive clinical trials. A growing list of experimental treatments, from antivirals and metformin to microbiome therapies and biologics, shows early promise. But turning those targets into tested, approved medicines takes time.
One practical finding stands out: structured rehabilitation and pacing can improve quality of life for long COVID patients. That matters, because well-meaning doctors have sometimes told long COVID patients to push through it with exercise. The science now suggests a more careful, guided approach is needed.
What comes next
The convergence of evidence from multiple high-quality sources around inflammation and fibrin-driven microclots represents a genuine scientific advance. It gives researchers specific molecular targets to aim at. But the gap between understanding a disease mechanism and having a treatment you can prescribe is enormous.
Sixty-five million people are waiting on the other side of that gap. What do you think it will take to move from mechanistic breakthroughs to actual therapies for long COVID?
Comments